Im Y, Lee J, Kim SJ, et al. - In order to gain a better understanding of tuberculosis (TB) development in cancer patients receiving immune checkpoint inhibitors (ICIs), researchers investigated 1,144 solid-cancer patients who initiated ICIs (pembrolizumab, nivolumab, or atezolizumab) between July 2014 and December 2018, to assess the development of TB in these individuals. The study sample comprised of lung cancer (n = 796, 69.6%) cases the most, followed by cases with melanoma (n = 115, 10.1%), and lymphoma (n = 85, 7.4%), with a median age of 62 years at the commencement of ICI treatment. The patients were administered ICIs for a median duration of 42 days (IQR; 18–154 days) and were observed for a median duration of 187 days (IQR; 70–342 days) following the start of ICIs. TB developed in 3 patients, two of whom were treated with nivolumab and one who received pembrolizumab. This shows that TB development is possible in cancer patients receiving ICIs. However, the small sample size did not allow experts to draw accurate conclusions regarding the role of ICIs in the development of TB. Moreover, it was unclear if the incidence of TB would be comparable with the incidence of TB in elderly cancer patients.